CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,798 enrolled
Drug / intervention
Nintedanibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05022784
NCT05022784N/ACompleted
CompareCT.gov

Real-World Medication Adherence Trajectories to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients

Boehringer Ingelheim·observational·Posted Aug 26, 2021·Updated Apr 19, 2024

In Brief

An observational study evaluating Nintedanib for Idiopathic Pulmonary Fibrosis. Completed, enrolled 1,798 participants across 1 site.

Detailed Summary

This is a non-interventional cohort study using existing administrative data from the U.S. Medicare program. This study has two objectives: * Identification of adherence trajectories of nintedanib among Idiopathic Pulmonary Fibrosis (IPF) patients. * Understanding characteristics of patients within each nintedanib adherence trajectory among IPF patients.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedAug 26, 2021
Enrollment StartAug 23, 2021
Primary CompletionDec 30, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 4.9 years ago

Interventions

Nintedanibdrug

Nintedanib